BACKGROUND: Neopterin, produced by human monocytes/macrophages upon stimulation by interferon-gamma, is a sensitive marker for monitoring Th1-cell immune response in humans. In malignant diseases, the frequency of increases in neopterin in the serum and urine of patients depends on tumor stage and type. METHODS: In a retrospective study comprising 129 females with breast cancer, urinary neopterin/creatinine ratios were measured at the time of diagnosis. Tumor characteristics were determined concomitantly. RESULTS: Urinary neopterin was increased in 18% of the patients. It did not correlate with tumor size or lymph node status, but it was influenced by the presence of distant metastases (P <0.05) and by tumor differentiation (P = 0.01). When product-limit estimates were calculated after follow-up for up to 13 years (median follow-up, 56 months), the presence of distant metastases (P <0.001), neopterin (P <0.001), tumor size (P = 0.001), and lymph node status (P <0.01) were significant predictors of survival. By multivariate analysis, a combination of the variables presence of distant metastases (P <0. 001), neopterin (P <0.01), and lymph node status (P <0.05) was found to jointly predict survival. In lymph node-negative patients without distant metastases, the relative risk of death associated with increased neopterin concentrations was 2.5 compared with patients with neopterin concentrations within the reference interval. CONCLUSION: Urinary neopterin provides additional prognostic information in patients with breast cancer.
BACKGROUND:Neopterin, produced by human monocytes/macrophages upon stimulation by interferon-gamma, is a sensitive marker for monitoring Th1-cell immune response in humans. In malignant diseases, the frequency of increases in neopterin in the serum and urine of patients depends on tumor stage and type. METHODS: In a retrospective study comprising 129 females with breast cancer, urinary neopterin/creatinine ratios were measured at the time of diagnosis. Tumor characteristics were determined concomitantly. RESULTS: Urinary neopterin was increased in 18% of the patients. It did not correlate with tumor size or lymph node status, but it was influenced by the presence of distant metastases (P <0.05) and by tumor differentiation (P = 0.01). When product-limit estimates were calculated after follow-up for up to 13 years (median follow-up, 56 months), the presence of distant metastases (P <0.001), neopterin (P <0.001), tumor size (P = 0.001), and lymph node status (P <0.01) were significant predictors of survival. By multivariate analysis, a combination of the variables presence of distant metastases (P <0. 001), neopterin (P <0.01), and lymph node status (P <0.05) was found to jointly predict survival. In lymph node-negative patients without distant metastases, the relative risk of death associated with increased neopterin concentrations was 2.5 compared with patients with neopterin concentrations within the reference interval. CONCLUSION: Urinary neopterin provides additional prognostic information in patients with breast cancer.
Authors: Hira Mohyuddin; Polymnia Georgiou; Abhishek Wadhawan; Melanie L Daue; Lisa A Brenner; Claudia Gragnoli; Erika F H Saunders; Dietmar Fuchs; Christopher A Lowry; Teodor T Postolache Journal: Pteridines Date: 2017-12-02 Impact factor: 0.581
Authors: Bohuslav Melichar; Martina Spisarová; Marie Bartoušková; Lenka Kujovská Krčmová; Lenka Javorská; Hana Študentová Journal: Ann Transl Med Date: 2017-07
Authors: Mya Sanda Thein; Anita Kohli; Rohit Ram; Maria Clara Ingaramo; Alka Jain; Neal S Fedarko Journal: Cancer Biomark Date: 2017-07-04 Impact factor: 4.388
Authors: Liye Chen; Xin Zeng; Jihui Wang; Simon S Briggs; Eric O'Neill; Jiliang Li; Russell Leek; David J Kerr; Adrian L Harris; Shijie Cai Journal: Am J Pathol Date: 2010-09-16 Impact factor: 4.307
Authors: Katharina Schroecksnadel; Michael Fiegl; Karin Prassl; Christiana Winkler; Hubert A Denz; Dietmar Fuchs Journal: J Cancer Res Clin Oncol Date: 2007-03-14 Impact factor: 4.553
Authors: T T Sahin; O Yuksel; G Girgin; H Sipahi; K Dikmen; C Azili; F Taneri; T Baydar Journal: J Endocrinol Invest Date: 2009-02 Impact factor: 4.256